Navigation Links
Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
Date:5/25/2011

HORSHAM, Pa., May 25, 2011 /PRNewswire/ -- A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA(abiraterone acetate) plus prednisone compared to patients treated with prednisone plus placebo.  The COU-AA-301 study was sponsored by Ortho Biotech Oncology Research & Development, unit of Cougar Biotechnology, Inc.

Results of the pivotal Phase 3, randomized, placebo-controlled, multicenter study showed that at pre-specified interim analysis, treatment with ZYTIGA in combination with prednisone resulted in a 35.4 percent reduction in the risk of death (14.8 months vs. 10.9 months [hazard ratio (HR) = 0.65; 95 percent CI: 0.54, 0.77; p<0.001]) and a 3.9 month difference in median survival compared to placebo plus prednisone.

The most common adverse events identified by the authors were fatigue, back pain, nausea, constipation, bone pain and arthralgia, which occurred at similar frequency in both arms.  Urinary tract infections were more frequent in the ZYTIGA arm.  Adverse events associated with elevated mineralocorticoid levels due to CYP17 inhibition (fluid retention and edema, hypokalemia and hypertension), as well as cardiac disorders and liver-function test abnormalities were deemed of special interest and were more common in the ZYTIGA arm.  Additional information is included in the Important Safety Information below.

"Given that men with metastatic castration-resistant prostate cancer have few options, we are pleased with the results of this rigorous study, which show that abiraterone acetate may extend survival in these patients," said Johann S. de Bono, MD, FRCP, MSc, PhD, The Institute for Cancer Research, The Royal
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 EHE International, the recognized ... nationwide physician network, today announced that David Abrams M.D ... named an EHE-certified preventive care center. Through David Abrams ... region now have greater access to EHE,s preventive care ... "EHE is proud to add Dr. Abrams M.D. to its ...
(Date:9/16/2014)... BOSTON , Sept. 16, 2014 QPID ... a move to new headquarters in Boston ... The new headquarters will be at 175 Franklin Street in ... operations and marketing teams. QPID Health,s new Southern ... Parkway in Carlsbad.  The expansion will help meet the demands ...
(Date:9/16/2014)... 2014  Decision Resources Group finds that the rheumatoid arthritis (RA) ... to over $18.2 billion in 2023 in the United ... , Italy , Spain ... Japan . TNF-alpha inhibitors will remain the leading drug class ... growth will be constrained and patient shares will decline due to ...
Breaking Medicine Technology:EHE International Certifies David Abrams M.D. as Its Newest Partner 2QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3
... myeloma is one,of the most common and devastating bone ... dramatically over the past decade. Recent,analyses suggest that this ... aggressive therapeutic interventions such as stem cell transplantation,according to ... the,official journal of the American Society of Hematology., ...
... 1 Regado Biosciences today announced,the enrollment ... open-label,randomized Phase IIa clinical study, named REVERSAL-PCI, ... enrolled at Black Hills Cardiology,in Rapid City, ... undergoing elective,Percutaneous Coronary Intervention (PCI) to assess ...
Cached Medicine Technology:Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 2Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 3Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 4Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System 2Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System 3
(Date:9/16/2014)... 2014 An experienced review website, ... and announced that Bluehost and HostGator.com are among ... want to purchase high quality web hosting (including ... visit their websites now. , BlueHost ( ... established itself as a reliable and long-standing force ...
(Date:9/16/2014)... Pulmonary Hypertension Association Travels to San Diego for ... Patients and Families to Help Fight Rare Lung Disease , ... pulmonary hypertension association that works to find ways to prevent ... lungs that affects the functioning of the heart and can ... only 2.8 years. , What:, PHA On The ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 ... hosting suppliers from the USA and announces ... ) are the best Windows web hosting ... on offering worldwide clients high quality WordPress ... low rates. , HostMonster provides outstanding ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... human papillomavirus (HPV), which is linked to the risk of ... that testing urine for HPV has good accuracy when compared ... lead researcher Dr. Neha Pathak. She is a resident in ... of London, England. The test could be done at ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: BlueHost and HostGator.com Are Among the Best Hosting Suppliers in 2014 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Best Windows Web Hosting Suppliers Recommended By SEO Hosting Review Site Top10BestSEOHosting.com 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2
... Modifying gene called Foxp3 may develop cells capable of ... -- New understanding about how to control autoimmune responses ... arthritis (RA), British researchers say. , RA -- a ... body,s immune system attacks itself. A molecule called Foxp3 ...
... financial, operational, and clinical visibility to ... ... Fla., Nov. 13 Sentry Data Systems,today announced HealthBIT, a ... and clinical,visibility to hospitals by qualifying, aggregating, and comparing their,data ...
... Found with Free, Online Resources -, White ... paying out-of-pocket to fill prescriptions, and with those ... "Safe,Strategies for Drug Savings" today on its site ... in the U.S., Canada, and other,countries as well, ...
... Access to the Power of the Xevo TQ System,s Quantitative ... ... MILFORD, Mass., Nov. 13 Focused on the,process of helping firms ... ) will showcase innovative,UltraPerformance LC(R) (UPLC) and mass spectrometry (MS) solutions ...
... suite enables payors to compete like ... evolving healthcare marketplace, BURLINGTON, Mass., Nov. 13 ... platform for healthcare payors,today announced that it will ... 2008 Gartner Healthcare Summit. The,conference will be held ...
... Patients with advanced non-small cell lung cancer whose ... rate of tumor shrinkage and a longer interval ... standard second-line erlotinib therapy, according to a study ... Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and ...
Cached Medicine News:Health News:New Therapy Could Transform Arthritis Treatment 2Health News:Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform 2Health News:PharmacyChecker.com Publishes 'Safe Strategies for Drug Savings' to Help All Americans Get Affordable Medication 2Health News:Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008 2Health News:Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008 3Health News:HealthEdge(R) Presents Award-Winning HealthRules(R) Technology Platform at the 2008 Gartner Healthcare Summit 2
80 inch PVC tubing with connectors and 19 gauge straight, beveled cannula. Fits Bausch & Lomb Surgical cassettes. Allows the safe removal of silicone oil in 10 minutes or less. 3/Box...
... gauge, 25 mm cannula with 30 gauge, 4.76 ... mm flattened tip. Cannula is attached to a ... ID x 8 inch long), for use with ... other vitreo-retinal membranes using visco elastic materials. Flattened, ...
20 gauge x 25 mm cannula with 30 degree x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
Medicine Products: